1. Home
  2. OCGN vs EU Comparison

OCGN vs EU Comparison

Compare OCGN & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ocugen Inc.

OCGN

Ocugen Inc.

HOLD

Current Price

$1.60

Market Cap

387.3M

Sector

Health Care

ML Signal

HOLD

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$3.17

Market Cap

464.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCGN
EU
Founded
2013
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Other Metals and Minerals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
387.3M
464.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OCGN
EU
Price
$1.60
$3.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$7.00
$4.00
AVG Volume (30 Days)
6.2M
3.1M
Earning Date
03-04-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,370,000.00
$44,142,000.00
Revenue This Year
$35.88
$17.41
Revenue Next Year
N/A
$95.45
P/E Ratio
N/A
N/A
Revenue Growth
14.26
N/A
52 Week Low
$0.52
$1.01
52 Week High
$1.96
$4.19

Technical Indicators

Market Signals
Indicator
OCGN
EU
Relative Strength Index (RSI) 51.41 62.84
Support Level $1.57 $3.06
Resistance Level $1.70 $3.58
Average True Range (ATR) 0.14 0.22
MACD -0.02 0.03
Stochastic Oscillator 22.45 57.22

Price Performance

Historical Comparison
OCGN
EU

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.

Share on Social Networks: